Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E126, Bethesda, MD 20892, UNITED STATES.

Non-USPS mail such as FedEx, UPS and other private carriers please use Rockville, MD 20850.

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Genitourinary Malignancies Branch (GMB) plans to procure one (1) Brand Name or Equal Life Technologies GeneTitan Multi-Channel (MC) System.

This is a combined synopsis/solicitation for commercial items, prepared in accordance with format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. 75N91019Q00046 includes all applicable provisions and clauses in effect through FAR FAC 2019-03 (June 2019) simplified procedures for commercial items.

The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees.

Only one award will be made as a result of this solicitation. This will be awarded as a Severable Firm Fixed Price type contract.

DESCRIPTION OF REQUIREMENT

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Genitourinary Malignancies Branch (GMB) plans to procure one (1) Brand Name or Equal Life Technologies GeneTitan Multi-Channel (MC) System. As the Clinical Center (CC) expands efforts to provide accurate and comprehensive genotyping for patients enrolling on clinical trials, the NCI Genitourinary Malignancies Branch (GMB) has a need to acquire an instrument that can read Pharmacoscan arrays - the state of the art genotyping technology for such an application. The NCI's current technology is outdated and does not provide sufficient coverage, or in some cases inaccurate reads for this application. The NCI intends to use this instrument in the research setting to discover potentially important gene-drug interactions that underlie interpatient variability observed in clinical trials underway at the NIH.

PRODUCT FEATURES/SALIENT CHARACTERISTICS

The following product features and salient characteristics are required for the Brand Name or Equal Life Technologies GeneTitan Multi-Channel (MC) System:

• Assessment of 4,627 genetic markers of drug variability (in 1,191 genes), 99% of  which are included in the CPIC, PharmGBK, and PharmADME working groups recommendations list.
• The aforementioned genetic markers are frequently found in association with variability in drug disposition and outcomes in the research setting. Thus, assessing genotype at these markers is important for discovery of variants that explain variability in the NIH clinical trials.
• The Pharmacoscan microarray is able to assess all known pharmacogenetic drug markers in a single assay.
• The instrumentation shall complete all steps for hybridization, washing, and imaging without user intervention and shall be compatible with microarrays for pharmacogenomics, customizable cancer genetic analysis, expanded carrier screening, and genome-wide association studies for targeted populations.
• All shipping, delivery, installation and training costs must be included in the quote. The NCI will not be responsible after award is made, if shipping costs are not included.
• Coordination of delivery, installation and training with the NCI Technical Point of Contact.

DELIVERY / INSTALLATION

The Contractor shall deliver the systems within two (2) weeks after award to:

National Cancer Institute
8560 Progress Drive
Frederick, Maryland 21701

TRAINING

The Contractor shall provide training on proper use of the highly specialized equipment, software and related at above location within one (1) week of installation. The training will be provided by a premium support scientist, or other Contractor personnel, on an as need be basis.

PAYMENT

Payment shall be made in arrears after delivery and acceptance of the NCI TPC. Payment authorization requires submission and approval of invoice to the NCI TPC and NIH Commercial Accounts.

BASIS OF AWARD

The purchase order will be awarded to the Lowest Price Technically Acceptable (LPTA). The award will be made on the basis of the lowest evaluated price of quotations meeting or exceeding the acceptability standards for the requirements/technical specifications stated above. The technical evaluation will be a determination based on information furnished by the vendor. The Government is not responsible for locating or securing any information which is not identified in the quote. The Government reserves the right to make an award without discussions.

PROVISIONS AND CLAUSES

The following FAR provisions and clauses apply to this acquisition:

FAR 52.211-6 Brand Name or Equal. (Aug 1999)
(a) If an item in this solicitation is identified as "brand name or equal," the purchase description reflects
the characteristics and level of quality that will satisfy the Government's needs. The salient physical,
functional, or performance characteristics that "equal" products must meet are specified in the
solicitation.
(b) To be considered for award, offers of "equal" products, including "equal" products of the brand name
manufacturer, must-
(1) Meet the salient physical, functional, or performance characteristic specified in this solicitation;
(2) Clearly identify the item by-
(i) Brand name, if any; and
(ii) Make or model number;
(3) Include descriptive literature such as illustrations, drawings, or a clear reference to previously
furnished descriptive data or information available to the Contracting Officer; and
(4) Clearly describe any modifications the offeror plans to make in a product to make it conform to the
solicitation requirements. Mark any descriptive material to clearly show the modifications.
(c) The Contracting Officer will evaluate "equal" products on the basis of information furnished by the offeror
or identified in the offer and reasonably available to the Contracting Officer. The Contracting Officer is
not responsible for locating or obtaining any information not identified in the offer.
(d) Unless the offeror clearly indicates in its offer that the product being offered is an "equal" product, the
offeror shall provide the brand name product referenced in the solicitation.

Offerors providing an "equal" product must submit additional documentation that highlights and describes how the offer is equal in accordance with FAR Clause 52.211-6.

52.212-1 INSTRUCTIONS TO OFFERORS-COMMERCIAL ITEMS (OCT 2018);

52.212-2 EVALUATION COMMERCIAL ITEMS (OCTOBER 2014):

52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS-COMMERCIAL ITEMS (OCT 2018) WITH DUNS NUMBER ADDENDUM {52.204-6 (OCT 2016)};

FAR Clause 52.212-4 CONTRACT TERMS AND CONDITIONS - COMMERCIAL ITEMS (OCT 2018);

FAR Clause 52.212-5: CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT STATUTES OR EXECUTIVE ORDERS-COMMERCIAL ITEMS (JAN 2019). The following FAR clauses cited in paragraph (b) of the clause at FAR 52.212-5 are also applicable to this acquisition;

FAR Clause 52.203-6 Restrictions on Subcontractor Sales to the Government (Sept 2006) with Alternate I (Oct 1995)

FAR Clause 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2018)

FAR Clause 52.209-6 Protecting the Government's Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment (Oct 2015)

FAR Clause 52.219-4 Notice of Price Evaluation Preference for HUBZone Small Business Concerns (Oct 2014)

FAR Clause 52.219-8 Utilization of Small Business Concerns (Oct 2018)

FAR Clause 52.219-28 Post Award Small Business Program Representation (Jul 2013)

FAR Clause 52.222-3 Convict Labor (June 2003)

FAR Clause 52.222-19 Child Labor - Cooperation with Authorities and Remedies (Jan 2018)

FAR Clause 52.222-21 Prohibition of Segregated Facilities (Apr 2015)

FAR Clause 52.222-26 Equal Opportunity (Sept 2016)

FAR Clause 52.222-35, Equal Opportunity for Veterans (Oct 2015)

FAR Clause 52.222-36 Equal Opportunity for Workers with Disabilities (July 2014)

FAR Clause 52.222-37 Employment Reports on Veterans (Feb 2016)

FAR Clause 52.222-40 Notification of Employee Rights Under the National Labor Relations Act (Dec 2010)

FAR Clause 52.222-50 Combating Trafficking in Persons (Mar 2015)

FAR Clause 52.223-18 Encouraging Contractor Policies to Ban Text Messaging While Driving (AUG 2011)

FAR Clause 52.225-1, Buy American Act--Supplies (May 2014)

FAR Clause 52.225-13 Restrictions on Certain Foreign Purchases (June 2008)

Far Clause 52.232-33 Payment by Electronic Funds Transfer-System for Award Management (SAM) (Oct 2018)

SUBMISSION INFORMATION

Quotations must be submitted via email to Contract Specialist, Kathy Elliott, at [email protected] in MS Word or Adobe Portable Document Format (PDF), no later than 11:00 AM EST, on Thursday, June 27, 2019. All responses must be received by the specified due date and time in order to be considered. QUOTATIONS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED. No collect calls will be accepted.

Please refer to solicitation no: 75N91019Q00046 on all correspondence.

Full text copies of the representations and certifications for other cited provisions and clauses may be obtained on line at the NCI website at http://ncioa.cancer.gov/oa-internet/reference.jsp

OFFERORS: Offers must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide a copy of the valid certification registrations of the offeror's Excluded Parties List System (EPLS) and Online Representations and Certifications Applications (ORCA) through www.sam.gov.